Chargement de l’entreprise
Just reported
Q3 2026 results
From Immunome's results release of 9 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
0,00 $US
Guided
—
No guide given
EPS, GAAP
Actual
-0,76 $US
Guided
—
No guide given
Operating income, GAAP
Actual
-90,4M $US
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Immunome is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B $USA+
EXELExelixis, Inc.16,8B $USA+
JAZZJazz Pharmaceuticals plc15,5B $USA
TECHBIO-Techne Corp11,4B $USA+
HALOHalozyme Therapeutics, Inc.11,4B $USA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Comment elle gagne de l'argent
- Research collaboration payments (historical)
En concurrence avec
- MKKGYMerck KGaA (through SpringWorks Therapeutics)
- 2616CStone Pharmaceuticals
- Ratio Therapeutics
Ce qu'elle vend6
Varegacestat
An investigational, once-daily pill being developed to treat desmoid tumors, which can grow into nearby tissue.
IM-1021
An experimental antibody-drug conjugate designed to carry cancer-killing medicine to cells with the ROR1 marker; it is being tested in people with lymphoma and solid tumors.
IM-1617
An experimental antibody-drug conjugate designed to target a receptor found on some solid tumors.
Afficher 3 de plus
IM-3050
An experimental treatment that uses a molecule aimed at the FAP marker to deliver radioactive lutetium-177 to cells in solid tumors.
IM-1340
An experimental antibody-drug conjugate being developed for solid tumors, including some lung and prostate cancers.
IM-1335
An experimental antibody-drug conjugate being developed to treat solid tumors; its target has not been publicly named.
Qui l'achète1
- AbbVie paid for research work under a collaboration agreement that ended in July 2025 (high confidence); Immunome has not reported product-sale customers.
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1Immunome relies on outside manufacturers for materials used in its named drug programs and expects to rely on them for future commercial supply.
- 2The IM-3050 clinical trial depends on third-party diagnostic radiotracer supply; its treatment also requires radioactive lutetium-177.
- 3Varegacestat is licensed from Bristol Myers Squibb, and Immunome owes that company royalties and potential milestone payments if the drug is developed and sold.
Ce qui pourrait mal tourner
- 1Varegacestat has not received marketing approval; the Food and Drug Administration could reject its application or require more information before a decision.
- 2Immunome has no product-sale revenue, reports continuing losses, and expects to need additional financing to fund development and potential commercialization.
- 3Drug development results are uncertain: clinical trials may not show adequate safety or benefit, and early results may not predict later trial outcomes.
À propos de Immunome Inc.
Immunome develops medicines intended to treat cancer. Its main drug candidate, varegacestat, is an investigational pill for desmoid tumors; the company has submitted a marketing application in the United States. Its other experimental treatments include drugs designed to deliver cancer-killing medicine or radiation to tumors.
- Siège
- Exton, Pennsylvania, United States
- Fondée en
- 2006
- Cotée sur
- Nasdaq
- Clôture de l'exercice
- December 31
Construit à partir des documents déposés par Immunome Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
